June 20-21, 2024, Hannover
© LuckyStep / Juliia, stock.adobe.com
Our scientific event for experts in lung research
Let's dive deep again into the research of lung diseases - this year with a focus on
The scientitic programm will be accompanied by poster exhibition and session, whichwill be taking place on June 20, 2024.
We look forward to welcoming you in June in Hannover!
Click here to read the program.
Online registration via the ticketing platform Fienta: Link to the ticket platform
General terms and conditions / data protection information:
Early-bird registration until May 31, 2024:
- Participant from academia: 350 EUR
- Participant from industry: 450 EUR
Late registration from June 1, 2024:
- Participant from academia: 400 EUR
- Participant from industry: 500 EUR
For DZL members: Please send your request for the limited free codes by June 15, 2024 directly to: lung.ws@item.fraunhofer.de
Fees include the registration for Models of Lung Disease 2024, coffee breaks, lunch and a barbecue on June 20.
CRC Hannover - Clinical Research Center Hannover
Feodor-Lynen-Straße 15
30625 Hannover
June 20, 2024 - June 21, 2024
English
BREATH Hannover/German Center for Lung Research
as of May, 23, 2024; subject to change without notice
08:45 |
Welcome Norbert Krug and Armin Braun, Fraunhofer ITEM |
Session 1: Drug development for lung disease Chair: Jens Hohlfeld, Fraunhofer ITEM |
|
09:00 |
Development of mucosal vaccines based on attenuated influenza and coronaviruses |
09:30 |
Novel drug leads in the fight against invasive fungal infections |
10:00 |
On the edge of precision medicine in lung disease |
10:30 |
Coffee break |
Session 2: SPRIND: A quantum shift for new antiviral agents Chair: Katherina Sewald, Fraunhofer ITEM |
|
11:00 |
The Virus Trap - a broad-spectrum antiviral platform |
11:30 |
iGUARD – translational development of antiviral RNAi |
12:00 |
Bifunctional peptides - a natural boost for our mucus |
12:30 |
CRISPR/Cas13-mediated antiviral therapy (CRISPR ANTIVIRALS) |
13:00 |
Lunch |
Session 3: Understanding and fighting infections Chair: Franziska Dahlmann, Fraunhofer ITEM |
|
14:00 |
Alveolar macrophage-expressed Plet1 is a driver of lung epithelial repair after viral pneumonia |
14:30 |
Novel insights into the druggability of Pseudomonas aeruginosa UDP-glucose pyrophosphorylase |
15:00 |
Integrated in-vitro / ex-vivo assessment of efficacy and respiratory toxicity for accelerated respiratory drug development |
15:30 |
Coffee break |
16:00 |
Translational research in advanced human tissue models for antifibrotic drug discovery |
16:30 |
Insights into the human metapneumovirus glycointeractome: a novel avenue for antiviral drug design |
17:00 |
Models of acute and chronic bacterial lung infections to assess the efficacy of inhaled antimicrobials |
17:30 Poster session - Snacks and drinks Chair: Thomas Tschernig, University of Saarland (Germany) |
|
18:30 |
Guided tours to different non-clinical and clinical departments of Fraunhofer ITEM:
|
19:30 |
Award to the best posters |
19:40 |
Outdoor barbecue at CRC Hannover |
21:30 |
Summary and conclusion day 1 Armin Braun, Fraunhofer ITEM |
08:00 |
Guided tours to different non-clinical and clinical departments of Fraunhofer ITEM:
|
Session 3: Understanding and fighting infections (continued) Chair: Franziska Dahlmann, Fraunhofer ITEM |
|
09:00 |
Targeted RNS therapeutics |
Session 4: Understanding the mechanisms of onset and exacerbation in asthma, COPD and lung fibrosis Chair: Antje Prasse, Fraunhofer ITEM |
|
09:30 |
Drug development in COPD |
10:00 |
How do recent clinical trial results influence the evolution of preclinical assays and the projects that they support? |
10:30 |
Cross-Talking between micro CT and lung disease animal models |
11:00 |
Coffee break |
11:30 |
Combined rhinovirus infection and cigarette smoke exposure of normal human epithelial cells and distal lung tissue ex vivo induces dysregulation of human airway basal cells Philipp Mroch, Fraunhofer ITEM |
12:00 |
Disease characterization and biomarker discovery toward precision medicine of fibrosis |
12:30 |
Ultrastructure meets transcriptomics |
13:00 |
Multiscale and multiomics analysis of lung fibrosis progression |
13:30 |
End |
Fraunhofer Institute for Toxicology and Experimental Medicine
